(Q33204138)

23 July 2017

1 reference

title

Anti-TNF-alpha therapy in ankylosing spondylitis (English)

1 reference

23 July 2017

0 references

ankylosing spondylitis

1 reference

1

Daniel Wendling

1 reference

23 July 2017

Eric Toussirot

2

1 reference

23 July 2017

language of work or name

English

0 references

publication date

1 July 2004

1 reference

Expert Opinion on Pharmacotherapy

23 July 2017

published in

1 reference

23 July 2017

volume

5

1 reference

23 July 2017

issue

7

1 reference

23 July 2017

page(s)

1497-1507

1 reference

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria

23 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1497

Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1497

Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromsø, northern Norway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1497

Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1497

A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1497

Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1497

Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1497

Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1497

Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1497

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1497

Treatment of ankylosing spondylitis with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1497

Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1497

Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1497

Bone mineral density improvement in spondyloarthropathy after treatment with etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1497

Local infusion of infliximab for the treatment of acute joint inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1497

Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1497

Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1497

Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1497

International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1497

Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1497

Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1497

Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1497

Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.7.1497

10.1517/14656566.5.7.1497

21 January 2018

Identifiers

DOI

1 reference

23 July 2017

1 reference